Darunavir-Ethanolate-TMC114-Ethanolate-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEDarunavir EthanolateCat. No.: HY-17041CAS No.: 635728-49-3Synonyms: TMC114 (Ethanolate)分式: CHNOS分量: 593.73作靶點(diǎn): HIV; HIV Protease作通路: Anti-infection; Metabolic Enzyme/Protease儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 mo

2、nths-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (84.21 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.6843 mL 8.4213 mL 16.8427 mL5 mM 0.3369 mL 1.6843 mL 3.3685 mL10 mM 0.1684 mL 0.8421 mL 1.6843 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和

3、給藥式選擇適當(dāng)?shù)娜芙獍福渲魄罢?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (4.21 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (4.21 mM); Cl

4、ear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (4.21 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Darunavir Ethanolate (TMC114 Ethanolate)種于治療和預(yù)防HIV/AIDS的HIV蛋酶抑制劑。對(duì)野型HIV-1蛋酶的Ki值為1 nM。IC50 & Target Ki: 1 nM (WT HIV-1 protease) 1體外研究

5、Darunavir is a broad-spectrum potent inhibitor active against HIV-1 clinical isolates with minimal cytotoxicity.Darunavir forms hydrogen bonds with the conserved main-chain atoms of Asp29 and Asp30 of the protease.These interactions are proposed to be critical for the potency of this compound agains

6、t HIV isolates that areresistant to multiple protease inhibitors 1. In an in vitro study in MT-2 cells, the potency of darunavir isgreater than that of saquinavir, amprenavir, nelfinavir, indinavir, lopinavir and ritonavir. Darunavir is primarilymetabolized by the hepatic cytochrome P450 (CYP) enzym

7、es, primarily CYP3A. The boosting dose ofritonavir acts an an inhibitor of CYP3A, thereby increasing darunavir bioavailability 2.體內(nèi)研究 Darunavir is effective against wild-type and PI-resistant HIV, and has an oral bioavailability of 37%. It needsto be combined with ritonavir, which increases the bioa

8、vailability to 82% 3.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) J Neuroimmune Pharmacol. 2019 Jul 23.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Tie Y, et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical

9、strains. J Mol Biol. 2004 Apr 23;338(2):341-52.2. McKeage K, et al. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503.3. Bhalekar MR, et al. In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir. Drug Deliv. 2016Sep;23(7):2581-2586.McePdfHeightCaution: Product has not been fully validated for medi